![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TNFAIP8L3 |
Gene summary for TNFAIP8L3 |
![]() |
Gene information | Species | Human | Gene symbol | TNFAIP8L3 | Gene ID | 388121 |
Gene name | TNF alpha induced protein 8 like 3 | |
Gene Alias | TIPE3 | |
Cytomap | 15q21.2 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A1B0GTK8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
388121 | TNFAIP8L3 | HCC1 | Human | Liver | HCC | 2.53e-11 | 1.38e+00 | 0.5336 |
388121 | TNFAIP8L3 | HCC2 | Human | Liver | HCC | 1.60e-10 | 8.16e-01 | 0.5341 |
388121 | TNFAIP8L3 | HCC5 | Human | Liver | HCC | 1.47e-12 | 6.00e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
GO:00192162 | Liver | HCC | regulation of lipid metabolic process | 181/7958 | 331/18723 | 4.58e-06 | 5.79e-05 | 181 |
GO:001087621 | Liver | HCC | lipid localization | 228/7958 | 448/18723 | 1.80e-04 | 1.41e-03 | 228 |
GO:01200092 | Liver | HCC | intermembrane lipid transfer | 33/7958 | 48/18723 | 2.12e-04 | 1.63e-03 | 33 |
GO:003367411 | Liver | HCC | positive regulation of kinase activity | 230/7958 | 467/18723 | 1.72e-03 | 8.95e-03 | 230 |
GO:000686921 | Liver | HCC | lipid transport | 198/7958 | 398/18723 | 1.92e-03 | 9.78e-03 | 198 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNFAIP8L3 | SNV | Missense_Mutation | novel | c.46N>C | p.Cys16Arg | p.C16R | Q5GJ75 | protein_coding | deleterious_low_confidence(0.01) | benign(0.047) | TCGA-05-4390-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
TNFAIP8L3 | SNV | Missense_Mutation | c.746N>A | p.Ile249Asn | p.I249N | Q5GJ75 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-44-2657-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TNFAIP8L3 | SNV | Missense_Mutation | c.562N>A | p.Glu188Lys | p.E188K | Q5GJ75 | protein_coding | deleterious(0.04) | possibly_damaging(0.828) | TCGA-86-7701-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | etoposide | PD | |
TNFAIP8L3 | SNV | Missense_Mutation | novel | c.640G>C | p.Glu214Gln | p.E214Q | Q5GJ75 | protein_coding | deleterious(0.01) | probably_damaging(0.961) | TCGA-CN-A6V1-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Immunotherapy | erbitux | CR |
TNFAIP8L3 | SNV | Missense_Mutation | novel | c.55N>C | p.Glu19Gln | p.E19Q | Q5GJ75 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-DQ-5630-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TNFAIP8L3 | SNV | Missense_Mutation | c.608N>T | p.Thr203Ile | p.T203I | Q5GJ75 | protein_coding | tolerated(0.37) | benign(0.045) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TNFAIP8L3 | SNV | Missense_Mutation | rs762065818 | c.652G>A | p.Asp218Asn | p.D218N | Q5GJ75 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-F1-6177-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |